Immunotherapy and chemotherapy before surgery for colorectal cancer with liver spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (PD-1 antibody), two types of immune-boosting drugs (rhG-CSF and IL-2), and chemotherapy (CapeOX) given before surgery for colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and improve outcomes, and it is designed for patients whose cancer can be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a confirmed diagnosis of colorectal adenocarcinoma (a type of colorectal cancer).
- Your cancer must be proficient mismatch repair (pMMR) or have low microsatellite instability (MSI-L) or be microsatellite stable (MSS) — this is a lab test result.
- You must have liver metastases that appeared at the same time as the primary colorectal cancer (synchronous).
- Your doctors must believe it is possible to achieve no evidence of disease (NED, meaning all visible cancer is removed) after treatment.
- You must have a certain clinical risk score (CRS) of 3-4 points.
- You must be in generally good physical condition (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests whether adding two targeted drugs (serplulimab and bevacizumab) to standard chemotherapy before surgery can improve outcomes for people with colorectal cancer that has spread to the liver. It is for those whose cancer has certain genetic features and is considered resectable.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This trial tests whether a drug called an immune checkpoint inhibitor (PD-1 blocker) can help lower the risk of cancer returning after surgery. It is for people with a specific type of colorectal cancer (dMMR or MSI-H) that had certain high-risk features.
This trial tests a new immunotherapy drug (tislelizumab) given before surgery for people with stage II or III colorectal cancer that has a specific DNA repair problem (dMMR/MSI-High). The drug aims to shrink the tumor and improve treatment outcomes.
This trial tests a new combination of two chemotherapy drugs (CAPOX) plus an immunotherapy drug (tislelizumab) before surgery for high-risk colon cancer that has not spread. It aims to see if adding tislelizumab helps shrink the tumor and lower the chance of the cancer coming back.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.